

July 2, 2026

<b>BSE Limited</b> <b>Listing Department-</b> <b>Phiroze Jeejeebhoy Tower,</b> <b>Dalal Street,</b> <b>Mumbai – 400 001,</b> <b>Scrip Code- 533543,</b>	<b>National Stock Exchange of India Ltd</b> <b>Exchange Plaza, C-1, Block G,</b> <b>Bandra Kurla Complex,</b> <b>Bandra (E)</b> <b>Mumbai – 400 051,</b> <b>Symbol: BROOKS</b>
------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Madam/ Sir,

**Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Incorporation of Wholly Owned Subsidiary**

Dear Sir/Madam,

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the applicable SEBI Circular, we wish to inform you that Brooks Laboratories Limited has incorporated a wholly owned subsidiary in the name of **ABRIDGE SPECIALITY LIMITED** on 2<sup>nd</sup> July 2026. The Certificate of Incorporation has been issued by the Ministry of Corporate Affairs on the same day.

The requisite details as required under Regulation 30 read with Schedule III of the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 Dated July 13, 2023, for incorporation of Wholly Owned Subsidiary Company are enclosed herewith as **Annexure – A**.

The above information is also being made available on the website of the Company.

Please take the above information on record.

Thanking You.

For **Brooks Laboratories Limited**,

**Krutika Rane**  
**Company Secretary and Compliance Office**  
**Membership No.: 66310**

**Annexure A**

**Details required under Regulation 30 read with Schedule III of the Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR") and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 Dated July 13, 2023.**

<b>Particulars</b>	<b>Details</b>
<b>Name of the target entity, details in brief such as size, turnover etc.</b>	Abridge Speciality Limited, a newly incorporated wholly owned subsidiary is incorporated as a Wholly Owned Subsidiary (WOS) of the Company on 2 <sup>nd</sup> July 2026. Authorised Share Capital: Rs. 1,00,000 (Rupees One Lakh). Turnover/Net worth: Not Applicable, since it is a newly incorporated company and is yet to commence its business operations.
<b>Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";</b>	<b>Brooks Laboratories Limited</b> , (the 'Company'/ 'BLL') is the promoter of <b>Abridge Speciality Limited</b> ('ASL'), a Wholly Owned Subsidiary. ASL is a Related Party. BLL would hold 100% share capital of ASL.
<b>Industry to which the entity being acquired belongs</b>	Manufacturing and Marketing of Pharmaceuticals and related products.
<b>Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);</b>	The incorporation of WOS aligns with the Company's strategic objective to expand its business.
<b>Brief details of any governmental or regulatory approvals required for the acquisition/incorporation;</b>	Not Applicable.
<b>Indicative time period for completion of the acquisition/incorporation.</b>	Not Applicable.
<b>Nature of Consideration - whether cash consideration or share swap or any other form and details of the same;</b>	The initial share capital subscribed at the time of Incorporation issued at face value.
<b>Percentage of shareholding / control acquired and / or number of shares acquired</b>	100%
<b>Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);</b>	Abridge Speciality Limited is recently incorporated and it is yet to commence its business. Therefore, the history of the last 3 years turnover is not available.